CTOs on the Move

ProSomnus

www.prosomnus.com

 
ProSomnus is the first manufacturer of precision, mass-customized Precision Oral Appliance Therapy devices to treat OSA, which affects over 74 million Americans and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity and type 2 diabetes. ProSomnus`s patented devices are a more comfortable and less invasive alternative to Continuous Positive Airway Pressure (CPAP) therapy, and lead to more effective and patient-preferred outcomes. With more than 150,000 patients treated, ProSomnus`s devices are the most prescribed Precision Oral Appliance Therapy in the U.S.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.prosomnus.com
  • 5675 Gibraltar Drive
    Pleasanton, CA USA 94588
  • Phone: 844.537.5337

Executives

Name Title Contact Details

Similar Companies

Seneca Medical

Seneca Medical is a Tiffin, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HistoRX

HistoRX is a Branford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oetiker Inc

Oetiker Inc is a Marlette, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hayden Medical Inc

Hayden Medical Inc is a Santa Clarita, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Motif Neurotech

Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.